CymaBay Therapeutics, Inc. – NASDAQ:CBAY
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 11 hours
CymaBay Therapeutics stock price monthly change
+35.56%
month
CymaBay Therapeutics stock price quarterly change
+97.61%
quarter
CymaBay Therapeutics stock price yearly change
+284.83%
year
CymaBay Therapeutics key metrics
Market Cap | 3.72B |
Enterprise value | 762.95M |
P/E | -7.31 |
EV/Sales | N/A |
EV/EBITDA | -5.53 |
Price/Sales | N/A |
Price/Book | 21.66 |
PEG ratio | -1.54 |
EPS | -1.05 |
Revenue | N/A |
EBITDA | -94.80M |
Income | -111.67M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCymaBay Therapeutics stock price history
CymaBay Therapeutics stock forecast
CymaBay Therapeutics financial statements
| Mar 2023 | 0 | -35.08M | |
|---|---|---|---|
| Jun 2023 | 31.01M | -808K | -2.61% |
| Sep 2023 | 0 | -33.88M | |
| Dec 2023 | 57K | -41.90M | -73512.28% |
| Sep 2025 | 15.47M | -60.58M | -391.4% |
|---|---|---|---|
| Dec 2025 | 28.29M | -78.02M | -275.78% |
| Mar 2026 | 39.03M | -42.64M | -109.24% |
| Jun 2026 | 68.87M | -19.87M | -28.86% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-07 | -0.3 | -0.32 |
|---|---|---|
| 2024-02-28 | -0.32 | -0.35 |
| Mar 2023 | 245319000 | 141.13M | 57.53% |
|---|---|---|---|
| Jun 2023 | 226650000 | 118.24M | 52.17% |
| Sep 2023 | 451048000 | 124.85M | 27.68% |
| Dec 2023 | 434686000 | 142.43M | 32.77% |
| Mar 2023 | 6.43M | -60.64M | 93.07M |
|---|---|---|---|
| Jun 2023 | -25.43M | 719K | 1.05M |
| Sep 2023 | -26.14M | 15.46M | 248.92M |
| Dec 2023 | -27.38M | -42.10M | 2.72M |
CymaBay Therapeutics alternative data
| Aug 2023 | 60 |
|---|---|
| Sep 2023 | 60 |
| Oct 2023 | 60 |
| Nov 2023 | 60 |
| Dec 2023 | 60 |
| Jan 2024 | 60 |
| Feb 2024 | 60 |
| Mar 2024 | 101 |
| Apr 2024 | 101 |
| May 2024 | 101 |
| Jun 2024 | 101 |
| Jul 2024 | 101 |
CymaBay Therapeutics other data
19.09%
-55.25%
of CBAY is owned by hedge funds
72
-46
16.76M
-48.50M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 0 | 100 |
| Apr 2023 | 0 | 120000 |
| May 2023 | 0 | 26749 |
| Jun 2023 | 0 | 26749 |
| Jul 2023 | 0 | 26749 |
| Aug 2023 | 0 | 47691 |
| Sep 2023 | 583771 | 93667 |
| Oct 2023 | 0 | 91604 |
| Nov 2023 | 0 | 88205 |
| Dec 2023 | 0 | 108694 |
| Jan 2024 | 0 | 28291 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | SHAH SUJAL director, officer.. | Common Stock | 1 | $2.94 | $3 | ||
Option | SHAH SUJAL director, officer.. | Common Stock | 2,288 | $5.78 | $13,225 | ||
Option | SHAH SUJAL director, officer.. | Common Stock | 22,076 | $4.05 | $89,408 | ||
Option | SHAH SUJAL director, officer.. | Common Stock | 14,372 | $8.43 | $121,156 | ||
Option | SHAH SUJAL director, officer.. | Common Stock | 3,125 | $11.69 | $36,531 | ||
Option | SHAH SUJAL director, officer.. | Common Stock | 18,899 | $9.21 | $174,060 | ||
Option | SHAH SUJAL director, officer.. | Common Stock | 52,084 | $1.72 | $89,584 | ||
Option | SHAH SUJAL director, officer.. | Common Stock | 14,625 | $1.06 | $15,503 | ||
Option | MCWHERTER CHARLES officer: Presiden.. | Employee Stock Option (right to buy) | 3,125 | $11.69 | $36,531 | ||
Option | MCWHERTER CHARLES officer: Presiden.. | Employee Stock Option (right to buy) | 2,778 | $1.72 | $4,778 |
| Patent |
|---|
Application Filling date: 29 Jan 2022 Issue date: 4 Aug 2022 |
Grant Filling date: 18 Sep 2020 Issue date: 18 Jan 2022 |
Grant Utility: Treatment of NAFLD and NASH Filling date: 19 Jun 2020 Issue date: 23 Nov 2021 |
Application Filling date: 12 May 2021 Issue date: 18 Nov 2021 |
Application Filling date: 12 May 2021 Issue date: 18 Nov 2021 |
Application Filling date: 21 Dec 2020 Issue date: 16 Sep 2021 |
Application Filling date: 3 Apr 2021 Issue date: 22 Jul 2021 |
Application Filling date: 12 Nov 2020 Issue date: 20 May 2021 |
Application Filling date: 12 Nov 2020 Issue date: 20 May 2021 |
Grant Filling date: 31 Oct 2018 Issue date: 18 May 2021 |
| Quarter | Transcript |
|---|---|
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 15 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 16 Mar 2023 | Q4 2022 Earnings Call Transcript |
CymaBay's Seladelpar: An Exceptional PPAR Agonist Candidate For PBC
Genfit: Major Data Release Before End Of Q2 Of 2023 Could Get Ball Rolling
CymaBay Therapeutics: Slow But Steady Progress
CymaBay: Long Term Is Constructive With Potential Seladelpar Conversion
CymaBay Therapeutics: Undiscovered Opportunity
CymaBay: Long-Term Potential Based On Prior PBC Trial Results
Adult Liver Diseases: The R&D Engine Drives Albireo's Long-Term Prospects.
Why I've Taken A 'Starter' Position In CymaBay Therapeutics
-
When is CymaBay Therapeutics's next earnings date?
Unfortunately, CymaBay Therapeutics's (CBAY) next earnings date is currently unknown.
-
Does CymaBay Therapeutics pay dividends?
No, CymaBay Therapeutics does not pay dividends.
-
How much money does CymaBay Therapeutics make?
CymaBay Therapeutics has a market capitalization of 3.72B. CymaBay Therapeutics made a loss 105.37M US dollars in net income (profit) last year or -$0.35 on an earnings per share basis.
-
What is CymaBay Therapeutics's stock symbol?
CymaBay Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "CBAY".
-
What is CymaBay Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of CymaBay Therapeutics?
Shares of CymaBay Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are CymaBay Therapeutics's key executives?
CymaBay Therapeutics's management team includes the following people:
- Mr. Sujal A. Shah Pres, Chief Executive Officer & Director(age: 52, pay: $820,570)
- Dr. Charles A. McWherter Ph.D. Chief Scientific Officer(age: 70, pay: $597,890)
- Mr. Paul T. Quinlan Gen. Counsel, Chief Compliance Officer & Corporation Sec.(age: 62, pay: $578,820)
-
How many employees does CymaBay Therapeutics have?
As Jul 2024, CymaBay Therapeutics employs 101 workers.
-
When CymaBay Therapeutics went public?
CymaBay Therapeutics, Inc. is publicly traded company for more then 11 years since IPO on 3 Feb 2014.
-
What is CymaBay Therapeutics's official website?
The official website for CymaBay Therapeutics is cymabay.com.
-
Where are CymaBay Therapeutics's headquarters?
CymaBay Therapeutics is headquartered at 7575 Gateway Boulevard, Newark, CA.
-
How can i contact CymaBay Therapeutics?
CymaBay Therapeutics's mailing address is 7575 Gateway Boulevard, Newark, CA and company can be reached via phone at +51 02938800.
CymaBay Therapeutics company profile:
CymaBay Therapeutics, Inc.
cymabay.comExchange:
NASDAQ
Full time employees:
101
Industry:
Biotechnology
Sector:
Healthcare
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
7575 Gateway Boulevard
Newark, CA 94560
Newark, CA 94560
CIK: 0001042074
ISIN: US23257D1037
CUSIP: 23257D103
